Former chief executive officer of Myotonic brings extensive experience in patient advocacy and community engagement
WALTHAM, Mass.– Dyne Therapeutics
, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Molly White as Vice President, Medical Communications and Advocacy. Ms. White previously served as chief executive officer of Myotonic (formerly the Myotonic Dystrophy Foundation), the world’s largest patient organization focused solely on myotonic dystrophy.
“We have a unique opportunity at Dyne to fundamentally change the course of serious muscle diseases and their impact on families and caregivers around the world,” said Ms. White. “I’m excited to join the dedicated team at Dyne and to support the advancement of our potentially transformative lead program in myotonic dystrophy type 1 (DM1), as well as our programs in Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), through meaningful engagement with the patient and scientific communities.”
“We’re thrilled to begin the year by adding Molly to our rapidly growing team at Dyne,” said Joshua Brumm, president and chief executive officer of Dyne. “With her experience leading Myotonic, Molly has demonstrated outstanding leadership and passionate advocacy in seeking to change the lives of those affected by myotonic dystrophy. We look forward to her contributions as we continue to build the leading muscle disease company and deliver on our sincere commitment to patients.”
Prior to joining Dyne, Ms. White served as chief executive officer of Myotonic, an organization dedicated to advancing research and enhancing the quality of life of people living with myotonic dystrophy. In that role, she led strategic direction and administrative oversight for the comprehensive programmatic and fundraising efforts of the foundation and its staff. Ms. White has over 25 years of leadership-level experience building, implementing and running award-winning domestic and international community programs for organizations in both the private and nonprofit sectors. She has created partnerships with a range of governmental, nonprofit and private sector stakeholders to launch initiatives targeting key national issues such as childhood obesity prevention and components of healthcare reform. Ms. White holds a B.A. from the University of Montana and an M.A. from the University of Iowa. She has received certification from the Center for Corporate Community Relations, Boston University and from the Fund Raising School, Center on Philanthropy, Indiana University. She has also served as a board member for numerous community organizations.
About Dyne Therapeutics
Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass. For more information, please visit www.dyne-tx.com
Ten Bridge Communications
Max Stendahl, 508-277-8117